Mobia Medical director buys 68,559 shares

Mobia Medical, Inc. director Casey M Tansey reported open-market purchases of 68,559 shares of common stock over three days in August 2026.

Rhea-AI Filing Summary

Mobia Medical, Inc. director Casey M Tansey reported open-market purchases of 68,559 shares of common stock over three days in August 2026. Transactions included 35,572 shares on August 13 at a weighted average price of $11.5073, 15,821 shares on August 14 at weighted average and fixed prices, and 17,166 shares on August 17 at a weighted average price of $11.8509. Footnotes state that several reported prices are weighted averages based on multiple trades within disclosed price ranges. The Rule 10b5-1 checkbox was not marked as an affirmatively adopted trading plan.

Insider Trade Summary

Net Buyer: 68,559 shares

Net Buy 4 txns

Insider Tansey Casey M

Role Director

Bought 68,559 shs ($797K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F3	17,166	$11.8509	$203K
Purchase	Common Stock F2	15,721	$11.65	$183K
Purchase	Common Stock	100	$12.53	$1K
Purchase	Common Stock F1	35,572	$11.5073	$409K

Holdings After Transaction: Common Stock — 301,891 shares (Direct)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.33 to $11.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.42 to $12.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.675 to $12.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Total shares purchased: 68,559 shares Shares purchased on August 13, 2026: 35,572 shares Weighted average price on August 13, 2026: $11.5073 per share +2 more

5 metrics

Total shares purchased 68,559 shares Aggregate net-buy across four open-market transactions in August 2026

Shares purchased on August 13, 2026 35,572 shares Common Stock, open-market purchases at weighted average price

Weighted average price on August 13, 2026 $11.5073 per share Price based on multiple trades from $11.33 to $11.685

Shares purchased on August 14, 2026 15,821 shares Includes 15,721 shares at weighted average $11.65 and 100 shares at $12.53

Shares purchased on August 17, 2026 17,166 shares Common Stock, open-market purchases at weighted average $11.8509

Key Terms

weighted average price, open market or private transaction, Rule 10b5-1

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction_code_description: Purchase in open market or private transaction"

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox is not marked as affirmed"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MOBI director Casey M Tansey report in this Form 4?

Casey M Tansey reported 68,559 shares of Mobia Medical, Inc. (MOBI) common stock purchased in open-market transactions over three days in August 2026, with multiple trades executed at various prices within disclosed ranges.

On what dates did Casey M Tansey buy MOBI shares and in what amounts?

Purchases occurred on August 13, 14, and 17, 2026. Reported amounts were 35,572 shares on August 13, 15,821 shares on August 14 (including a 100-share trade), and 17,166 shares on August 17, all in Mobia Medical common stock.

What prices were paid for the MOBI shares reported in this Form 4?

Reported prices include weighted average prices of $11.5073, $11.6500, and $11.8509 per share, plus a 100-share trade at $12.53. Footnotes explain these are weighted averages from multiple trades within specified price ranges.

Were the MOBI insider purchases by Casey M Tansey made under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmed under a trading plan. Footnotes describe weighted average pricing but do not state that the transactions were executed pursuant to a Rule 10b5-1 trading arrangement.

What is the total net share change reported for MOBI in this Form 4?

The transaction summary shows a net-buy of 68,559 shares of Mobia Medical, Inc. common stock. All four reported transactions are coded as open-market or private purchases, with no sales, exercises, or gifts disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 09:54 PM EDT Accepted by SEC EDGAR 08/17/2026 - 09:53 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tansey Casey M

(Last) (First) (Middle)

2802 FLINTROCK TRACE, SUITE 226

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mobia Medical, Inc. [ MOBI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		P		35,572	A	$11.5073(1)	268,904	D
Common Stock	08/14/2026		P		15,721	A	$11.65(2)	284,625	D
Common Stock	08/14/2026		P		100	A	$12.53	284,725	D
Common Stock	08/17/2026		P		17,166	A	$11.8509(3)	301,891	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.33 to $11.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.42 to $12.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.675 to $12.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Chase Leavitt, Attorney-in-Fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)